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Background: There are inconsistencies in the determinants of adherence to antiretrovirals (ARVs) across settings as
well as a lack of studies that take into consideration factors beyond the individual level. This makes it necessary to
examine factors holistically in multiple settings and populations while taking into consideration the particularities of
each context, in order to understand the patterns of ARV adherence. This research explored ARV adherence and
individual, relational and environmental-structural factors.
Methods: A cross-sectional survey was conducted from August 2008 through July 2009 among participants
currently on ARVs recruited from 6 public health clinics, selected to maximize diversity in terms of caseload and
location, representing the range of clinics within Rio de Janeiro city, Brazil. Multivariate logistic regression analysis
was used to assess the association between our multilevel factors with ARV adherence among participants with
complete cases (n = 632).
Results: Eighty-four percent of respondents reported adherence to all of their ARV doses in the last 4 days. Of the
socio-demographic variables, those who had one child were positively associated with adherence (AOR 2.29 CI
[1.33-3.94]). On the relational level, those with high social support (AOR 2.85 CI [1.50-5.41]) were positively
associated with adherence to ARVs. On the environmental-structural level, we found gender was significant with
women negatively associated with adherence to ARVs (AOR 0.58 CI [0.38-0.88]) while those with a high asset index
(AOR 2.47 CI [1.79-3.40]) were positively associated with adherence to ARVs.
Conclusions: This research highlights the importance of examining the multiple levels of influence on ARV
adherence. Intervention research in lower and middle-income settings should address and evaluate the impact of
attending to both gender and economic inequalities to improve ARV adherence, as well as relational areas such as
the provision of social support.
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Brazil is a pioneer in providing universal free access to
antiretrovirals (ARVs). Despite continued concerns about
the financial sustainability of the ARV program, Brazil has
been able to implement a successful program with mortality
and morbidity among people living with HIV (PLWH)
dropping drastically since the mid-1990s [1,2]. While there* Correspondence: hhanif@jhsph.edu
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reproduction in any medium, provided the orhave been concerns that the roll-out of ARVs in resource-
limited settings would be associated with lower adherence
to ARVs, leading to drug resistance, data show that adher-
ence levels in resource-poor settings are similar to those in
resource-rich settings [3,4]. Brazil has demonstrated that
ARV therapy can be delivered in a resource limited setting
without creating widespread transmissions of resistant
strains [5-8]. The sustainability of Brazil’s universal provision
of ARVs is in question as case management becomes more
complex with more time on ARVs resulting in more side ef-
fects, an increase in ARV costs due to scaling up treatment,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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treatment [9]. Since a certain amount of drug resistance
can be attributed to low medication adherence, improving
adherence is an important factor in the overall sustainabil-
ity of the program. In addition, with the global roll-out of
ARVs ongoing, it is important to examine issues surround-
ing medication adherence in lower and middle-income
countries.
The introduction of combination ARVs changed the
progression of HIV to AIDS by increasing life expect-
ancy and making HIV a chronic disease requiring daily
medications [10-12]. While almost perfect adherence to
the complex regimen is required to maintain viral sup-
pression, a recent meta-analysis found an average rate of
adherence to ARVs at 62 percent worldwide [13]. Adher-
ence to ARVs has become an important area of research
because it is a strong predictor for progression to AIDS;
furthermore, adherence may be improved through care-
fully planned interventions [3,14-16]. While significant
research has been conducted on factors associated with
adherence to ARVs, a limited number of factors have
been consistently identified across multiple settings [17].
Taking into account the complex interplay of factors de-
termining adherence, researchers have categorized vari-
ables into groups such as: patient factors, medication
regimen, disease characteristics, patient-provider relation-
ship and the clinical setting [18,19]. Sociodemographic var-
iables have not been shown to consistently predict ARV or
other medication adherence; [20,21] though being male,
white, older, having higher income and higher literacy have
more often been associated with better adherence [22-24].
Psychosocial factors such as depression and psychiatric
disorders have been associated with poor medication ad-
herence [25-29]. Depression is associated with worse out-
comes, and has been associated with an accelerated decline
in CD4 count and HIV disease progression [30]. With re-
gard to relational factors, social support has been found to
be a significant determinant of adherence in several stud-
ies, with low levels of social support consistently predicting
nonadherence [25,31-34]. A systematic review of available
evidence in the PubMed database on socioeconomic status
(SES) and adherence to ARVs did not find a consistent as-
sociation but noted a positive trend between higher levels
of SES and adherence [35].
The literature on adherence in Brazil is not extensive and
is limited by varying definitions of adherence and popula-
tions sampled. While this is the case in the general adher-
ence literature, these limitations make it difficult to observe
patterns of adherence and limit generalizability for Brazil as
a whole. Studies in Brazil have identified a range of adher-
ence patterns, from 52 to 83 percent adherence, potentially
due to how adherence was measured [7,36]. The variables
found to be important are similar to those previously
discussed including a combination of patient, medicationand clinic level factors. Some of these factors are adherence
self-efficacy, frequency of dosing, medication beliefs, forget-
fulness, alcohol use, depression, unemployment and misun-
derstandings about the prescription [6,37-39]. One of the
largest studies was conducted by Nemes et al. [40], which
included patients under follow-up in health units from 7
Brazilian states with a sample size of 1,972. They found ad-
herence prevalence was 75 percent with non-adherence pre-
dicted by low levels of formal education, complex regimens,
and number of missed appointments. Another study in Rio
de Janeiro had high self-reported adherence at 82 percent,
with self-efficacy, sexual orientation, loss of appetite and the
doctor-patient relationship found to be significantly associ-
ated with adherence [8]. Research among low-income
women on ARVs in São Paulo found women had unmet
care needs regarding medical information and psychological
support, indicating the necessity of better integrating ser-
vices and increasing focus on women’s needs [41].
There have been a number of studies examining adher-
ence to ARVs across different countries and populations
and several systematic reviews regarding the determinants
of adherence to ARVs [17,32]. The many inconsistencies in
the determinants of adherence to ARVs have been attrib-
uted to the differences among populations, statistical
power and sampling methodology, the predictors included
and how they were conceptualized and measured, and how
adherence itself was measured. This makes it necessary to
examine factors holistically in multiple settings and popu-
lations while taking into consideration the particularities of
each context, in order to understand the patterns of ARV
adherence.
The research on adherence to ARVs in Brazil has focused
on patient factors and medication regimen with some re-
search on the clinic setting. In addition, most research has
been conducted in referral centers, such as University hos-
pitals and research centers. The majority of PLWH in
Brazil access care through the public clinics, which are
often located in impoverished communities and serve the
poor to low-middle class populations. This research con-
tributes to the understanding of ARV adherence among
men and women from a heterogeneous sample of public
clinics. We contextualized adherence behavior by examin-
ing multiple levels of influence such as environmental-
structural (economic and gender), relational (social sup-
port), and individual (sociodemographic and psychosocial)
factors. The aim is to understand the factors that facilitate
or impede adherence to develop more comprehensive care
and targeted interventions that better meet the needs of
PLWH accessing care through public clinics.
Methods
Participants and procedures
This analysis is part of a larger study by the Oswaldo
Cruz Foundation focusing on the psychosocial and
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wellbeing of people living with HIV/AIDS receiving
treatment from public health clinics in Rio de Janeiro
city. The study recruited 900 participants, of whom 650
were currently on ARV. This analysis focuses on complete
case participants on ARVs (n = 632).
Eligible participants were at least 18 years of age, had
a confirmed HIV-positive status, received HIV treatment
and care from a public health clinic, and were willing to
provide consent. The participants were recruited from
six key public health facilities of the total 29 health cen-
ters managed by the Rio de Janeiro Health Secretariat.
These clinics are located in the urban area of the muni-
cipality of Rio. All clinics included in this study are sec-
ondary level clinics, which provide care for many
different conditions above a primary care clinic. All ser-
vices are free, including all medications for HIV/AIDS
and other chronic conditions such as diabetes and
hypertension. Insurance is not required. The six clinics
were selected based on caseload (smaller versus larger
clinics) and location (geographic and administrative), en-
suring a heterogeneous sample representing the range of
clinics. These six facilities provide care for approximately
60 percent of the over 14,000 patients living with HIV/
AIDS receiving follow-up. The study received ethical ap-
proval from the Institutional Review Boards (IRB) of the
Johns Hopkins School of Public Health, the Oswaldo
Cruz Foundation, the Municipal Health Secretariat, and
the National IRB of the Brazilian Ministry of Health.
A pilot test using focus groups was conducted in each
clinic before survey implementation to ensure clarity of the
questionnaire. Once the questionnaire was finalized, the
survey was conducted from August 2008 through July
2009. A trained supervisor recruited participants in the
waiting area of the clinics. The purpose of the survey was
explained to potential participants and any questions were
answered. After oral consent was given, the participant was
taken to a private room where a trained interviewer went
through the consent form and obtained written consent.
The questionnaire took approximately 50 minutes to
complete. Interview responses were recorded on Teleform®
scannable data forms and reviewed by the interviewer for
completeness and consistency prior to the participant’s de-
parture. The forms were scanned for computer entry by
the project coordinator.
Measures
Measures in the survey included sociodemographic vari-
ables as well as psychological well-being, measured by anx-
iety and depression, social support and economic factors.
The dependent variable, ARV adherence, and measure de-
tails are listed below.
Socio-demographic and Background Variables: Ana-
lysis variables included: age, race/ethnicity, education,sexual orientation, relationship status, HIV status of
partner, number of children, and length of time on
ARVs.
Psychological Well-Being: The Hospital Anxiety and
Depression Scale (HAD) is a tested tool to measure psy-
chological well-being over the past week, especially for
chronic conditions, and has been used in Brazil
[8,39,42]. This scale is composed of 14 questions divided
into an anxiety subscale and a depression subscale to
identify possible and probable cases of anxiety and
depression among non-psychiatric patients. Physical
symptoms are not included in this scale (e.g. headaches,
insomnia, fatigue). Responses are rated on a 4 point
scale (hardly at all to most of the time) and include items
such as: “I felt tense or wound-up;” “I enjoyed the things
I use to;” “I had worrying thoughts go through my
mind;” “I felt cheerful;” and “I could sit at ease and
relax.” This study used 11 as the cutoff for possible de-
pression (Cronbach’s alpha = .76) or anxiety (Cronbach’s
alpha = .81), respectively [43].
Social support: The social support measure consisted
of nine questions from the Medical Outcomes Study
(MOS) social support survey developed for chronic con-
ditions [44] which has been validated in Brazil [45], as
well as four additional questions to strengthen the tan-
gible support aspect of the measure including perceived
support in relation to obtaining medication, monetary
aid, housing, and overall satisfaction with support. Re-
spondents answered on a five point scale how often in
the last month each kind of support was available to
them. The scale had a Cronbach’s alpha of .90 and was
categorized into low, medium, and high support based
on the distribution.
Gender: Divided into 3 categories: male, female or
transgendered persons.
Economic Factors: Personal income (type and amount)
and household income was measured as well as having sav-
ings. An asset based wealth (SES) index was used based on
the IBGE (Brazilian Institute of Geography and Statistics)
consisting of ownership of household items such as a radio,
TV, refrigerator, etc. The index ranged from 1 to 23 with a
median of 7 items and had a Cronbach’s alpha of .77. The
index was dichotomized at the median into low and high
asset levels.
ARV adherence: A modified AIDS Clinical Trial
Group’s (ACTG) questionnaire was used to measure
medication adherence [46] which has been used in pre-
vious studies in Brazil [47]. The questions focus on re-
cent adherence to minimize recall bias. The outcome
adherence was measured by the question: In the last four
days, how many days did you take all of your doses of all
of your HIV medications? The measure was dichoto-
mized into adherent if the response was 4 days and non-
adherent if anything else was chosen.
Table 1 Sample characteristics in study of PLWH on ARVs













Non-White (Black, Brown, Other) 463 73%
Education
Primary or less 278 44%
Secondary 262 41%
University or more 92 15%
Sexual Orientation
Heterosexual 374 59%
Other (Homosexual, Bi, Trans) 258 41%
Relationship Status
No Steady Partner 325 51%











Other (Espirita, Afro-Brasilian, other) 141 22%
None 81 13%
Length of time on ARVs [range: 0–23years; median: 6]
0-1yrs 147 23%
2-6yrs 199 32%
7-23 yrs 286 45 %
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Data were analyzed using the statistical software Stata11.0
[48]. Descriptive analysis was conducted to examine the
distribution of the data such as frequencies, medians, and
ranges. Aggregate measures were developed using reliabil-
ity analysis to assess internal consistency.
Bivariate statistical tests such as t-tests (for continuous
variables) and chi-square tests (for categorical variables)
were utilized to characterize the direction and signifi-
cance of the relationship between major study variables,
as was bivariate logistic regression. All significant vari-
ables of p-value less than 0.10 from the bivariate analysis
were included in the multivariate analysis, as well non-
significant variables hypothesized to be confounders or
effect modifiers based on findings from previous re-
search, or included for conceptual purposes. Multivariate
logistic regression analysis was conducted to assess the
adjusted association between the primary independent
variables and the dependent variable, adherence to
ARVs. All independent variables were assessed for collin-
earity by examining their correlation coefficients. Indi-
viduals who receive services from the same clinic may
be more similar with regard to adherence to ARVs, cre-
ating a potential clustering effect. The variance-
covariance estimate (VCE) command was used to adjust
for this within clinic intraclass correlation [49,50].
Results
Socio-demographic characteristics of the respondents
are presented in Table 1. The participants ranged in age
from 19 to 67 years, with a median age of 42 years. The
majority was male (68%) and there were more heterosex-
ual (59%) than homosexual, bisexual, or transgendered
participants. Education levels were relatively low with
only about 15 percent having achieved University level
or more. Monthly income ranged from 0 to 4,790 USD
(median 365 USD) with the majority classified in low
socio-economic status based on the asset index. The
sample was about evenly divided between those with or
without a steady sexual partner. Of those with steady
partners, only 13 percent were also HIV positive. About
half the population did not have a child. Length of time
on ARVs ranged from less than one year to 23 years,
with a median of 6 years.
Eight-four percent of respondents self reported adher-
ence to all of their ARV doses in the last four days.
About 85 percent said they followed specific dosing in-
structions all or a majority of the time in the last four
days. When asked the last time they missed taking any
of their medications, 32 percent of respondents said they
had never missed a dose, 35 percent more than a month
prior, while 21 percent missed a dose in the past week.
Only 17 percent of the sample missed a dose on the
weekend. The most recent viral load measurements fromthe past year were obtained from respondents’ medical
records. Self reported adherence was significantly corre-
lated with viral load data (Pearson r=.22; p<.0001).
Those with undetectable viral loads were twice as likely
to self-report perfect adherence to ARVs in the last 4
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[1.33-3.22]).
Bivariate associations between the independent vari-
ables and ARV adherence are presented in Table 2. Of
the socio-demographic variables, older age, having two
or more children, and a high education level were sig-
nificantly associated with adherence. Thirty-five percent
and 70 percent of respondents presented symptoms of
moderate to severe anxiety and depression, respectively.
Only anxiety was significantly associated with adherence
but depression was still included in the multivariate
model. High social support was significantly associated
with adherence. In the bivariate analysis of the economic
variables, having savings and high asset levels were signifi-
cantly associated but individual, household or types of in-
come were not significantly associated with adherence.
Gender was significantly associated with adherence.
In the multivariate analysis, as presented in Table 2,
the model included socio-demographic variables, depres-
sion and anxiety, social support, gender, and economic
factors. Of the sociodemographic variables, those who
had one child (AOR 2.29 CI [1.33-3.94]) were positively
associated with adherence but the same association did
not apply to those who had two or more children com-
pared to those who had no children. Those with high so-
cial support were significant associated with adherence
than those with low social support (AOR 2.85 CI [1.50-
5.41]). Of the economic factors, having a high asset
index was independently associated with adherence than
a low index (AOR 2.47 CI [1.79-3.40]). Gender was sig-
nificantly associated with the outcome, with women less
likely to be adherent to ARVs (AOR 0.58 CI [0.38-0.88]).
Discussion
Self-reported adherence was high and comparable to other
studies in Brazil [8,36,51]. We found that women were
negatively associated with adherence to ARVs in this set-
ting. While SES factors have not been consistently associ-
ated with adherence, we found a high asset index to be
significantly associated with adherence. In addition social
support was found to be significantly associated with the
outcome, which is consistent with research among PLWH
in other settings. Sociodemographic factors have generally
not been consistently associated with adherence; we only
found number of children to be significant which will be
discussed in relation to gender. These factors and their re-
lationships, especially pertaining to the history of the epi-
demic in Brazil and particularities of the research setting,
will be discussed.
Women are especially vulnerable to HIV and negative
HIV-related outcomes such as biological factors due to
toxicity and social factors due to gender inequality
[52-54]. A recent study examined factors associated with
ARV discontinuation or modification and found womenhad a higher hazard for short-term toxicity [55]. In
addition, women were found to have more severe side-
effects than men, leading to higher rates of ARV discon-
tinuation among women. Furthermore, there is a
“feminization” of the epidemic with the male to female
ratio decreasing from 5.9:1 in 1989 to 1.4:1 in 2006,
highlighting the importance of increasing focus of re-
search and interventions on women in Brazil [56].
Women might also experience challenges in accessing
ARVs due to lack of knowledge, stigma and discrimin-
ation [57,58]. The history of activism in the Brazilian
AIDS community started within the gay community and
focused on MSM early on in the epidemic [59]. Women
have not had the same amount of support from NGOs
and most of the attention in Brazil to date among
women has been on prevention efforts, which has also
been the case globally [60,61].
We found having one child was associated with being ad-
herent, versus not having any children, but the same did
not apply for those having two or more children. A study
in the US found that the number of children living at home
is associated with nonadherence, and caretaking of chil-
dren is often the responsibility of women [62]. Upon fur-
ther analysis, adjusting for additional life stressors, the
study still found the presence of children and not other
stressors associated with nonadherence [62]. It appears
that women place others’ needs, especially their children’s,
ahead of their own [62,63]. While having at least one child
in our study is associated with adherence, it might be a
proxy for something else, such as stability in their life, but
more than one child may create an extra burden. The role
of caretaking and number of children warrants further re-
search with regard to their role on adherence to ARVs
among women in Brazil.
The pattern of the Brazilian HIV epidemic seems to ini-
tially affect higher socioeconomic levels and then dissem-
inate into poorer populations [1,64]. This can be seen in
the difference between the southeastern region where the
epidemic began and is now among the middle and lower
class versus the northeastern region where the epidemic is
more recent and is concentrated in higher socioeconomic
populations [1,65]. Even within our lower income popula-
tion, respondents with higher levels of assets were signifi-
cantly more likely to be adherent. This signifies the need to
understand how wealth plays a role in adherence even in
the context of free health services and free medication. So-
cioeconomic factors often serve as a proxy for other bar-
riers to adherence such as transportation costs, lack of
time, difficulty obtaining health information, and discrim-
ination [66]. Poverty increases vulnerability to HIV infec-
tion and can also make it harder to cope with a complex
chronic infection [67].
Social support is a multidimensional construct that
has been defined and measured in various ways, focusing
Table 2 Bivariate and multivariate analysis of individual, relational, and environmental-structural variables on the
outcome: adherence to ARVs (n = 632)
% Adherent UOR (95% CI) p-value AOR (95% CI) p-value
Individual variables
Sociodemographics
Age [range = 19-67 years; median = 42]
19-35 78% 1.00 1.00
36-41 81% 1.20 (.67 - 2.12) 0.543 1.40 (.59 - 3.33) 0.451
42-47 87% 1.88 (1.04 - 3.38) 0.037 1.86 (.88 - 3.95) 0.104
48-67 85% 1.57 (.89 - 2.79) 0.122 1.52 (.72 - 3.22) 0.268
Race
White 86% 1.00 1.00
Non-White (Black, Brown, Other) 82% 0.72 (.44 - 1.89) 0.200 0.82 (.43 - 1.59) 0.562
Education
Primary or less 80% 1.00 1.00
Secondary 86% 1.52 (.97 - 2.39) 0.068 1.19 (.92 - 1.53) 0.187
University or more 88% 1.90 (.95 - 3.80) 0.070 0.89 (.58 - 1.36) 0.580
Sexual orientation
Heterosexual 81% 1.00 1.00
Other (Homosexual, Bi, Trans) 86% 1.42 (.92 - 2.20) 0.116 1.08 (.58 - 1.99) 0.817
Relationship status
No Steady Partner 84% 1.00 1.00
With Steady Partner 82% 0.85 (.56 - 1.29) 0.455 0.73 (.46 - 1.14) 0.167
Partner HIV status
HIV negative 84% 1.00 1.00
HIV positive 79% 0.71 (.40 - 1.26) 0.244 0.71 (.43 - 1.17) 0.178
Number of children
0 85% 1.00 1.00
1 89% 1.40 (.73 - 2.69) 0.315 2.29 (1.33 - 3.94) 0.003
>=2 78% 0.65 (.42 - 1.03) 0.066 1.25 (.78 - 2.01) 0.363
Religion
Catholic 83% 1.00 1.00
Evangelical 82% 0.94 (.56 - 1.59) 0.824 1.12 (.60 - 2.09) 0.731
Other (Espirita, Afro-Brazilian, other) 84% 1.03 (.59 - 1.80) 0.914 0.91 (.30 - 2.72) 0.862
None 84% 1.05 (.53 - 2.08) 0.886 1.04 (.47 - 2.32) 0.921
Length of time on ARVs
0-1 yrs 80% 1.00 1.00
2-6 yrs 85% 1.50 (.86 - 2.64) 0.155 1.53 (.88 - 2.65) 0.128
7-23 yrs 84% 1.30 (.78 - 2.17) 0.307 1.11 (.73 - 1.67) 0.629
Psychosocial variables
Depression
No (<11) 83% 1.00 1.00
Depressed (>11) 83% 0.98 (.62 - 1.54) 0.932 0.89 (.51 - 1.54) 0.678
Anxiety
No (<11) 86% 1.00 1.00
Anxiety (>11) 79% 0.61 (.40 - .93) 0.021 0.76 (.51 - 1.54) 0.177
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Table 2 Bivariate and multivariate analysis of individual, relational, and environmental-structural variables on the
outcome: adherence to ARVs (n = 632) (Continued)
Relational variable
Social support
Low 76% 1.00 1.00
Medium 82% 1.46 (.91 - 2.33) 0.119 1.47 (.93 - 2.31) 0.096
High 91% 3.13 (1.67 -5.88) 0.000 2.85 (1.50 - 5.41) 0.001
Environmental-structural variables
Asset index
Low (1-7) 78% 1.00 1.00
High (8-23) 91% 2.89 (1.77 -4.73) 0.000 2.47 (1.79 - 3.40) 0.000
Savings
No 81% 1.00 1.00
Yes 91% 2.40 (1.30 -4.42) 0.005 1.81 (.93 - 3.53) 0.079
Gender
Male 86% 1.00 1.00
Female 76% 0.53 (.35 - .81) 0.004 0.58 (0.38 - .88) 0.011
Transgender 100% Predicts perfectly Predicts perfectly
UOR Unadjusted Odds Ratio, CI Confidence Interval, AOR Adjusted Odds Ratio.
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received [31]. Our measure was heavily focused on the
provision of tangible material support such as help with
obtaining medicines, performing chores, or going to the
doctor. This is key to understanding the kinds of support
important in addressing adherence. Future research
should examine potential differences in the kinds of sup-
port women receive versus men since women are often
the caretakers and carry a larger burden of household
responsibilities, while men might have more economic
burdens. Again, since the epidemic has reached women
more recently, their needs have not received the same
attention as other populations. They may not have the
same extra-familial support networks to go to for sup-
port as MSM have within AIDS activist organizations
within a setting such as Rio de Janeiro. In addition, fear
of stigma may inhibit accessing support from their net-
works [57,68,69].
There was a linear trend between social support and
assets, where those with more assets also had more so-
cial support. It is possible that participants with higher
levels of assets also have family and friends with higher
levels of assets; better enabling them to obtain the ne-
cessary support when needed. It is possible that those
who suffer material deprivation also do not have the
ability to access the necessary kinds of support from
their social surroundings due to the lack of available re-
sources. This can be potentially explained through the
components of social capital which can be seen as hori-
zontal or vertical, where linkages with people who are ofsimilar status or background is called bonding social
capital (horizontal) and people who are of a different
background or identity is called bridging social capital
(vertical) [70]. Further research in the realm of social
capital, where resources available to an individual come
from being a part of social networks, could help in un-
derstanding the relationship between assets and social
support to develop care and support interventions
among PLWH in lower income settings.
Anxiety and depression were not significant in the
final model but the high prevalence among PLWH in
this setting warrants further research. A recent study in
Brazil using the same depression and anxiety measure
but at a higher cutoff point to determine severe cases of
depression and anxiety, found a high prevalence of anx-
iety (35.8%) and depressive (21.8%) symptoms among
patients before initiating ARVS, which increased (51.5%
and 40.6%, respectively) in the 175 day follow-up time
period [39]. In addition, they found severe anxiety was
significantly associated with non-adherence but not se-
vere depression. We found similar anxiety levels in our
study but a much greater prevalence of depressive symp-
toms (70%). This may be due to the longer average treat-
ment duration among our study population since
depressive symptoms increased in the aforementioned
study over time.
Limitations
Adherence is a dynamic behavior but our analysis is only
cross-sectional; therefore we are only capturing one
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in our associations. While self-report tends to overesti-
mate adherence levels, it is reliable and tends to indicate
average adherence [19]. The AGTC questionnaire has
been tested in multiple settings and in Brazil as well. In
addition, the self-report of adherence in this study was
significantly correlated with the viral load data from
their medical records. We attempted to decrease social
desirability bias with a statement commenting on the
difficulty of adherence before asking our questions. We
also tried to limit recall bias by asking about adherence
in the previous four days. The findings from this study
come from regular clinics, where most Brazilians access
care across the different regions, and not referral cen-
ters, where most of the studies in Brazil are conducted.
Therefore these findings are more generalizable than
other studies in Brazil but since Rio de Janeiro is the
second largest city in Brazil, these findings should not be
generalized to either poorer areas inside Brazil or low-
income countries.
Conclusions
This research highlights the importance of examining the
multiple levels of influence on ARVs adherence. While the
population had a high adherence rate, women were nega-
tively associated with adherence compared to men,
highlighting the gendered dimensions of providing effect-
ive care and support to PLWH. Even within a relatively
poor population, having more wealth was associated with
adherence. It is important to understand how wealth plays
a role in adherence even in the context of free health
services and medication, and in relation to social sup-
port. Intervention research in this and similar settings
should address and evaluate the impact of attending
to both gender and economic inequalities to improve
ARV adherence and relational areas such as the pro-
vision of social support.Competing interests
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